¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2024 Ãá°è½ÉÇ÷°üÅëÇÕÇмú´ëȸ(2ÀÏÂ÷) : 2024-04-20

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

2024 Ãá°è½ÉÇ÷°üÅëÇÕÇмú´ëȸ(2ÀÏÂ÷) : 2024-04-20
±³À°ÀÏÀÚ : 2024-04-20
±³À°Àå¼Ò : °æÁÖ È­¹éÄÁº¥¼Ç¼¾ÅÍ (HICO)

±³À°ÁÖÁ¦ : 2024 Ãá°è½ÉÇ÷°üÅëÇÕÇмú´ëȸ(2ÀÏÂ÷)

ÁÖÃÖ±â°ü : ´ëÇѽÉÀåÇÐȸ
´ã´çÀÚ : Á¶À±ÇÏ
¿¬¶ôó : 02-3275-5258  

À̸ÞÀÏ : herz8@circulation.or.kr

±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, ÈäºÎ¿Ü°ú, ¿µ»óÀÇÇаú, ÀÇ»çÇÐ

Âü¼®¿¹»óÀÎ : 2000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡

Áö¿ª : °æ»óºÏµµ
±³À°½Ã°£ : 47 ½Ã°£ 20ºÐ

¼¼ºÎ¼ö°­·á : 150,000¿ø  

ºñ°í »çÀüµî·Ï: ±³¼ö ¹× °³¿øÀÇ 120000 / ÀüÀÓÀÇ,Àü°øÀÇ,±âŸ 70000ÇöÀåµî·Ï: ±³¼ö ¹× °³¿øÀÇ 150000 / ÀüÀÓÀÇ,Àü°øÀÇ,±âŸ 90000


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 04¿ù 20ÀÏ 102È£ 09:00~09:15 Left Main PCI ¹Ú½ÂÁ¤(¿ï»êÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 102È£ 09:15~09:30 Bifurcation PCI ³²Ã¢¿í(°è¸íÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 102È£ 09:30~09:45 CTO PCI À¯Ã¶¿õ(°í·ÁÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 102È£ 09:45~10:00 PCI for Severely Calcified Lesions ±ÇÇöö(¼º±Õ°üÀÇ´ë)

Åä·Ð 04¿ù 20ÀÏ 102È£ 10:00~10:30 Discussion ()

ÈÞ½Ä 04¿ù 20ÀÏ 10:30~10:40 Break ()

±³À°½Ã°£ 04¿ù 20ÀÏ 102È£ 10:40~11:00 Interventional Perspectives on Post-AMI Care: Bridging Clinical Needs with Advanced Imaging ÃÖ±âÈ«(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 102È£ 11:00~11:20 Echocardiographic Assessment in Post-AMI Patients: An Initial and Comprehensive Approach for High-Risk Stratification ¿ÀÁø°æ(Ãæ³²ÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 102È£ 11:20~11:40 Cardiac MRI in Post-AMI Evaluation: Insights into Myocardial Damage and Pathways to Recovery °­ÀºÁÖ(µ¿¾ÆÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 102È£ 11:40~12:00 The Role of Nuclear Imaging in Assessing Myocardial Viability and Functional Recovery Potential °øÀºÁ¤(¿µ³²ÀÇ´ë)

Åä·Ð 04¿ù 20ÀÏ 102È£ 12:00~12:10 Discussion ()

ÈÞ½Ä 04¿ù 20ÀÏ 12:10~12:15 Break ()

±³À°½Ã°£ 04¿ù 20ÀÏ 102È£ 12:15~12:35 CV Continuum: What Are the Gaps for The Ideal Patient Management? ÀÌÀåÈÆ(°æºÏÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 102È£ 12:35~12:55 Decoding the Future: The Potential of RNA-Based Treatments ±è¿µ±¹(Àü³²ÀÇ´ë)

ÈÞ½Ä 04¿ù 20ÀÏ 12:55~13:10 Break ()

±³À°½Ã°£ 04¿ù 20ÀÏ 102È£ 13:10~13:25 Periprocedural Functional and Imaging Asessement in Patients with Peripheral Arterial Disedase ÇÑÁø¿µ(ÀÎÁ¦ÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 102È£ 13:25~13:40 Recent Update in Drug Technology in Patient with Femoropopliteal Disease ÇÑÁ¤±Ô(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 102È£ 13:40~13:55 Debulking Procedure for Femoropliteal Disease - Efficacy and Implication À̽ÂÁØ(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 102È£ 13:55~14:10 Recent Advance in Endarterectomy and Bypass Surgery in Lower Extermity Disease ³ë¿µ³²(¿µ³²ÀÇ´ë)

Åä·Ð 04¿ù 20ÀÏ 102È£ 14:10~14:40 Discussion ()

ÈÞ½Ä 04¿ù 20ÀÏ 14:40~14:50 Break ()

±³À°½Ã°£ 04¿ù 20ÀÏ 102È£ 14:50~15:05 ´Ù¸®Ç÷°ü ¼Õ»ó (Iliac Artery Dissection and Rupture during TAVR) ÀÌöÇö(°è¸íÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 102È£ 15:05~15:20 ´ëµ¿¸Æ±â½ÃºÎ ¼Õ»ó (Annular Rupture during TAVR) Àå±âÀ°(¿ï»êÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 102È£ 15:20~15:35 °ü»óµ¿¸Æ ¼Õ»ó (Coronary Obsturction during TAVR ±è¿õ(¿µ³²ÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 102È£ 15:35~15:50 ŸºñÆǸ· ÀÌÅ» (Valve Migration during TAVR) ±èÁÖÇÑ(Àü³²ÀÇ´ë)

Åä·Ð 04¿ù 20ÀÏ 102È£ 15:50~16:20 Discussion ()

±³À°½Ã°£ 04¿ù 20ÀÏ 103È£ 09:00~09:20 Diagnosis and Optimal medical therapy of PAD ¹ÚÅñÔ(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 103È£ 09:20~09:40 Recent update of  intervention in PAD ¾Èö¹Î(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 103È£ 09:40~10:00 Overview and update of surgical intervention of PAD with case ±ÇÁر³(¿ï»êÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 103È£ 10:00~10:20 Overview and update of hybrid intervention of PAD with case ±èÅÂÈÆ(¿¬¼¼ÀÇ´ë)

Åä·Ð 04¿ù 20ÀÏ 103È£ 10:20~10:30 Discussion ()

ÈÞ½Ä 04¿ù 20ÀÏ 10:30~10:40 Break ()

±³À°½Ã°£ 04¿ù 20ÀÏ 103È£ 10:40~11:00 Marfan Syndrome ±èÇý¹Ì(Áß¾ÓÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 103È£ 11:00~11:20 Behcet's Disease ¼­Áö¿ø(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 103È£ 11:20~11:40 Takayasu's Arteritis ±è´ëÈñ(¿ï»êÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 103È£ 11:40~12:00 Fibromuscular Dysplasia ÀÌÇØ¿µ(¼­¿ïÀÇ´ë)

Åä·Ð 04¿ù 20ÀÏ 103È£ 12:00~12:10 Discussion ()

ÈÞ½Ä 04¿ù 20ÀÏ 12:10~12:15 Break ()

±³À°½Ã°£ 04¿ù 20ÀÏ 103È£ 12:15~12:35 Early Benefit of Lipitor in ACS Patients Sripal Bangalore(NYU School of Medicine, USA)

±³À°½Ã°£ 04¿ù 20ÀÏ 103È£ 12:35~12:55 Renal Safety Issues in Dyslipidemia Treatment: Why Is It Important Gyu Chul Oh(Catholic Univ., Korea)

ÈÞ½Ä 04¿ù 20ÀÏ 12:55~13:10 Break ()

±³À°½Ã°£ 04¿ù 20ÀÏ 103È£ 13:10~13:30 Genetic Cardiomyopathy Research Using iPCS-derived Cardiomyocyte ¿ÀÀç¿ø(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 103È£ 13:30~13:50 Application of Gene Editing in Genetic Cardiomyopathy ±è±ÔÈ£(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 103È£ 13:50~14:10 LMNA-Related Dilated Cardiomyopathy À̼ö¿ë(ºÎ»êÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 103È£ 14:10~14:30 Deep Dive into Sarcomere Genes Related to Cardiomyopathy ±è°æÈñ(ÀÎõ¼¼Á¾º´¿ø)

Åä·Ð 04¿ù 20ÀÏ 103È£ 14:30~14:40 Panel Discussion ()

ÈÞ½Ä 04¿ù 20ÀÏ 14:40~14:50 Break ()

±³À°½Ã°£ 04¿ù 20ÀÏ 103È£ 14:50~15:10 Must-Know Recent Pulmonary HTN Guideline - Focused on Changed and Unchanged Things ÀÌÁÖÈñ(ÃæºÏÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 103È£ 15:10~15:30 Basics of Echocardiography to Evaluate Pulmonary HTN ÃÖÈ«¹Ì(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 103È£ 15:30~15:50 How to Utilize the Right Tool to the Right Ventricular Function Evaluation ¹ÚÀçÇü(Ãæ³²ÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 103È£ 15:50~16:10 Interpretation of the Right Heart Catheterization Results - Case-based Learning À念¿ì(°¡ÃµÀÇ´ë)

Åä·Ð 04¿ù 20ÀÏ 103È£ 16:10~16:20 Panel Discussion ()

±³À°½Ã°£ 04¿ù 20ÀÏ 105È£ 09:00~09:20 Diagnosis of Chronic Venous Insufficiency and DVT: US & CT Venography ÀÌÀ±¼º(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 105È£ 09:20~09:40 Comprehesive  Care of DVT & Endovascular Treatment for DVT ±è¿ìÇö(ÇѾçÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 105È£ 09:40~10:00 Utility and Risks of Vena Cava Filters to Prevent PE ÃÖÀ±¼®(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 105È£ 10:00~10:20 Interventional Treatment of Chronic Thromboembolic Pulmonary Hypertension ¾Èö¹Î(¿¬¼¼ÀÇ´ë)

Åä·Ð 04¿ù 20ÀÏ 105È£ 10:20~10:30 Discussion ()

ÈÞ½Ä 04¿ù 20ÀÏ 10:30~10:40 Break ()

±³À°½Ã°£ 04¿ù 20ÀÏ 105È£ 10:40~11:00 Conduction System Pacing for PM Indication À̼ҷÉ(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 105È£ 11:00~11:20 Leadless and Extravascular CIEDs ±èÁÖ¿¬(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 105È£ 11:20~11:40 Optimizing Device Therapy for HF: BVP, CSP, LOT-CRT ¹Ú½ÂÁ¤(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 105È£ 11:40~12:00 Introduction to Remote Monitoring ±è´ëÈÆ(¿¬¼¼ÀÇ´ë)

Åä·Ð 04¿ù 20ÀÏ 105È£ 12:00~12:10 Discussion ()

ÈÞ½Ä 04¿ù 20ÀÏ 12:10~12:15 Break ()

±³À°½Ã°£ 04¿ù 20ÀÏ 105È£ 12:15~12:35 Focusing on NVAF Patients with Renal Impairment and Treatment with Well-balanced Apixaban À̼ҷÉ(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 105È£ 12:35~12:55 Optimizing Anticoagulation Management with Apixaban in AF Patients with High Bleeding Risk ¹Ú¿¹¹Î(°¡ÃµÀÇ´ë)

ÈÞ½Ä 04¿ù 20ÀÏ 12:55~13:10 Break ()

±³À°½Ã°£ 04¿ù 20ÀÏ 105È£ 13:10~13:30 ÆǸ·Áúȯ ÇÙ½ÉÁ¤¸®: ÆǸ·¿ª·ùÁõ ÀÌ»óÇö(ºÎ»êÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 105È£ 13:30~13:50 µÎ²¨¿öÁø ½É±Ù: °¨º°Áø´Ü°ú Ä¡·á Á¶Àͼº(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 105È£ 13:50~14:10 ½ÉºÎÀü Áø´Ü ±èÀÎö(°è¸íÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 105È£ 14:10~14:30 ½ÉºÎÀü Ä¡·á Á¶À翵(Àü³²ÀÇ´ë)

Åä·Ð 04¿ù 20ÀÏ 105È£ 14:30~14:40 Discussion ()

ÈÞ½Ä 04¿ù 20ÀÏ 14:40~14:50 Break ()

±³À°½Ã°£ 04¿ù 20ÀÏ 105È£ 14:50~15:10 Treatment of Hypertension in Elderly Persons ¹Ú»ó¹Î(À»ÁöÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 105È£ 15:10~15:30 Treatment of Resistant Hypertension ½ÅÁ¤ÈÆ(ÇѾçÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 105È£ 15:30~15:50 Treatment of Hypertension in Pregnant Women ±è¹Ì³ª(°í·ÁÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 105È£ 15:50~16:10 Treatment of Hypertension in Patients with High BP Variability Á¶Á¤¼±(°¡Å縯ÀÇ´ë)

Åä·Ð 04¿ù 20ÀÏ 105È£ 16:10~16:20 Discussion ()

±³À°½Ã°£ 04¿ù 20ÀÏ 202È£ 09:00~09:20 Recent Advances in the Management of Cardiogenic Shock Jacob C Jentzer(Mayo Clinic, USA)

±³À°½Ã°£ 04¿ù 20ÀÏ 202È£ 09:20~09:40 Hemodynamic Monitoring in Cardiogenic Shock Hyoung-Won Cho(Seoul National Univ., Korea)

±³À°½Ã°£ 04¿ù 20ÀÏ 202È£ 09:40~10:00 Treatment Strategy According to Cardiogenic Shock Phenotype Soo Yong Lee(Pusan National Univ., Korea)

±³À°½Ã°£ 04¿ù 20ÀÏ 202È£ 10:00~10:20 Application of Mechanical Circulatory Support in Cardiogenic Shock Sang Hyup Lee(Yonsei Univ., Korea)

Åä·Ð 04¿ù 20ÀÏ 202È£ 10:20~10:30 Discussion ()

ÈÞ½Ä 04¿ù 20ÀÏ 10:30~10:40 Break ()

±³À°½Ã°£ 04¿ù 20ÀÏ 202È£ 10:40~11:00 FH: Diagnostic Pitfalls and Practical Tips for Screening ÃÖ¼ºÈñ(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 202È£ 11:00~11:20 Pathogenesis & Genetics of FH: What ±èÈÖ½Â(Áß¾ÓÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 202È£ 11:20~11:40 Recent Update on FH Treatment õ´ë¿µ(ÇѸ²ÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 202È£ 11:40~12:00 Korean FH registry: Current Status and Future Perspectives ÀÌÂùÁÖ(¿¬¼¼ÀÇ´ë)

Åä·Ð 04¿ù 20ÀÏ 202È£ 12:00~12:10 Discussion ()

ÈÞ½Ä 04¿ù 20ÀÏ 12:10~12:15 Break ()

±³À°½Ã°£ 04¿ù 20ÀÏ 202È£ 12:15~12:45 Benefits of Intensive Lipid Lowering with Rosuvastatin and Ezetimibe Combination Therapy in ASCVD È«¼øÁØ(°í·ÁÀÇ´ë)

Åä·Ð 04¿ù 20ÀÏ 202È£ 12:45~12:55 Discussion ()

ÈÞ½Ä 04¿ù 20ÀÏ 12:55~13:10 Break ()

±³À°½Ã°£ 04¿ù 20ÀÏ 202È£ 13:10~13:30 Light: GLP1-RA should be used first Á¶µ¿Çõ(°í·ÁÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 202È£ 13:30~13:50 Shadow: GLP1-RA should be used in selected patients ÀÌÀº¿µ(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 202È£ 13:50~14:10 The use of GLP-1 RA is still a priority Á¶µ¿Çõ(°í·ÁÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 202È£ 14:10~14:30 The use of GLP-1 RA should be careful ÀÌÀº¿µ(°¡Å縯ÀÇ´ë)

Åä·Ð 04¿ù 20ÀÏ 202È£ 14:30~14:40 Discussion ()

ÈÞ½Ä 04¿ù 20ÀÏ 14:40~14:50 Break ()

±³À°½Ã°£ 04¿ù 20ÀÏ 202È£ 14:50~15:10 Initial Management & When Should You Refer for Emergent Surgery ÀÌÀçÇ×(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 202È£ 15:10~15:30 Schema of Various Operations & Their Characteristics ÀÌÄ¡ÈÆ(ºÎ»êÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 202È£ 15:30~15:50 Current Surgical Results for Acute Aortic Dissection Type A (AADTA) ÁÖÇöö(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 202È£ 15:50~16:10 Short-term & Long-term Management of Descending Aorta Involvement in AADTA ±èÅÂÈÆ(¿¬¼¼ÀÇ´ë)

Åä·Ð 04¿ù 20ÀÏ 202È£ 16:10~16:20 Discussion ()

±³À°½Ã°£ 04¿ù 20ÀÏ 204È£ 12:15~12:35 Cutting Edge Care of Pitavastatin with Ezetimibe Combination Therapy Á¶µ¿Çõ(°í·ÁÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 204È£ 12:35~12:55 Is There a Better Treatment Option for Dyslipidemia Patients with Impaired Glucose Metabolism ÃÖ±âÈ«(¼º±Õ°üÀÇ´ë)

ÈÞ½Ä 04¿ù 20ÀÏ 12:55~13:10 Break ()

±³À°½Ã°£ 04¿ù 20ÀÏ 205È£ 09:00~09:20 CAR-T Therapy Related Cardiac Complications Choon Ta Ng(National Heart Centre Singapore, Singapore)

±³À°½Ã°£ 04¿ù 20ÀÏ 205È£ 09:20~09:40 TKI and Proteasome Inhibitor and Pulmonary Hypertension Ji Hyun Lee(Dong-A Univ., Korea)

±³À°½Ã°£ 04¿ù 20ÀÏ 205È£ 09:40~10:00 Amyloidosis: When We Need Cardiologist? Sung Soo Park(Catholic Univ., Korea)

±³À°½Ã°£ 04¿ù 20ÀÏ 205È£ 10:00~10:20 Amyloidosis: When We Need Hematologist? Mi-Hyang Jung(Catholic Univ., Korea)

Åä·Ð 04¿ù 20ÀÏ 205È£ 10:20~10:30 Discussion ()

ÈÞ½Ä 04¿ù 20ÀÏ 10:30~10:40 Break ()

±³À°½Ã°£ 04¿ù 20ÀÏ 205È£ 10:40~11:00 Pediatric DCM: Classification and Diagnosis Min-Jung Cho(Gyeongsang National Univ., Korea)

±³À°½Ã°£ 04¿ù 20ÀÏ 205È£ 11:00~11:20 Cardiomyopathy in Duchenne Muscular Dystrophy Lucy Youngmin Eun(Yonsei Univ., Korea)

±³À°½Ã°£ 04¿ù 20ÀÏ 205È£ 11:20~11:40 Cardiomyopathy in Pediatric Cancer Patients Hee Joung Choi(Keimyung Univ., Korea)

±³À°½Ã°£ 04¿ù 20ÀÏ 205È£ 11:40~12:00 New Therapeutic Approach for Cardiomyopathy in Duchenne Muscular Dystrophy Jonathan Soslow(Vanderbilt Children's Hospital, USA)

Åä·Ð 04¿ù 20ÀÏ 205È£ 12:00~12:10 Discussion ()

ÈÞ½Ä 04¿ù 20ÀÏ 12:10~12:15 Break ()

±³À°½Ã°£ 04¿ù 20ÀÏ 205È£ 12:15~12:35 Empagliflozin, Cardio Renal Metabolic Disease Continuum and Management Chronic Heart Failure with CKD ¼­Á¤¼÷(ÀÎÁ¦ÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 205È£ 12:35~12:55 Deep Dive into Benefits of Empagliflozin as an 1st Line Treatment for Chronic Heart Failure ÃÖÈ¿ÀÎ(¼º±Õ°üÀÇ´ë)

ÈÞ½Ä 04¿ù 20ÀÏ 12:55~13:10 Break ()

±³À°½Ã°£ 04¿ù 20ÀÏ 205È£ 13:10~13:30 Arrhythmias in Pediatric DCMP ¹ÝÁöÀº(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 205È£ 13:30~13:50 Prognostic Role of RV Function in Dilated Cardiomyopathy ¹æÁö¼®(¼¼Á¾º´¿ø)

±³À°½Ã°£ 04¿ù 20ÀÏ 205È£ 13:50~14:10 RV Cardiomyopathy, Secondary to CHD: Prevention & Treatment Â÷½½±â(¿ï»êÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 205È£ 14:10~14:30 Pulmonary Artery Banding as an Alternative Strategy for Bridge-to-transplant/Recovery Patients with DCMP ½ÅÀ¯¸²(¿¬¼¼ÀÇ´ë)

Åä·Ð 04¿ù 20ÀÏ 205È£ 14:30~14:40 Discussion ()

ÈÞ½Ä 04¿ù 20ÀÏ 14:40~14:50 Break ()

±³À°½Ã°£ 04¿ù 20ÀÏ 205È£ 14:50~15:10 Dignositc Challages with Symptomatic Obstructive Hypertorphic Cardiomyopathy Á¤¼öÀÎ(¾ÆÁÖÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 205È£ 15:10~15:30 Predictive Value of Classic Sudden Death Risk Factors in Pediatric-onset Hypertrophic Cardiomyopathy ¼Û¹Ì°æ(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 205È£ 15:30~15:50 New Targeted Medication for HCMP ¾È°æÁø(°¡ÃµÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 205È£ 15:50~16:10 Septal Reduction Therapy and More Surgery in HCMP ÃÖÀº¼®(¿ï»êÀÇ´ë)

Åä·Ð 04¿ù 20ÀÏ 205È£ 16:10~16:20 Discussion ()

±³À°½Ã°£ 04¿ù 20ÀÏ 300B 09:00~09:20 Atrial Functional MR/TR: Pathophysiology and Risk Factors Iksung Cho(Yonsei Univ., Korea)

±³À°½Ã°£ 04¿ù 20ÀÏ 300B 09:20~09:40 Atrial Dysfunction in Significant Atrial Functional MR/TR Judy Hung(Massachusetts General Hospital, USA)

±³À°½Ã°£ 04¿ù 20ÀÏ 300B 09:40~10:00 Atrial Functional MR: When and How to Treat? Dae-Hee Kim(Ulsan Univ., Korea)

±³À°½Ã°£ 04¿ù 20ÀÏ 300B 10:00~10:20 Atrial Functional TR: When and How to Treat? Sung Hee Shin(Inha Univ., Korea)

Åä·Ð 04¿ù 20ÀÏ 300B 10:20~10:30 Discussion ()

ÈÞ½Ä 04¿ù 20ÀÏ 10:30~10:40 Break ()

±³À°½Ã°£ 04¿ù 20ÀÏ 300B 10:40~11:00 Image Acquisition in Aortic Stenosis: Pitfalls & Tips ¹Ú¼ºÁö(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 300B 11:00~11:20 Low Dose Dobutamine Echocardiography for Aortic Stenosis Á¶µ¿Çõ(°í·ÁÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 300B 11:20~11:40 Assessing Aortic Stenosis with Multi-modality Imaging ½ÉÁö¿µ(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 300B 11:40~12:00 Aortic Stenosis Quantification in Multi-valve Disease ¼±º´ÁÖ(¿ï»êÀÇ´ë)

Åä·Ð 04¿ù 20ÀÏ 300B 12:00~12:10 Discussion ()

ÈÞ½Ä 04¿ù 20ÀÏ 12:10~12:15 Break ()

±³À°½Ã°£ 04¿ù 20ÀÏ 300B 12:15~12:35 Single Pill Combination Treatment for Hypertension and Dyslipidemia ÀÌÇöÁ¤(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 300B 12:35~12:55 Benefits of Intensive Lipid Lowering Therapy with Ezetimibe/statin Combination ÀÌÁßÈñ(¿¬¼¼¿øÁÖÀÇ´ë)

ÈÞ½Ä 04¿ù 20ÀÏ 12:55~13:10 Break ()

±³À°½Ã°£ 04¿ù 20ÀÏ 300B 13:10~13:30 Up-to-date of Generative AI ÃÖÀ±Àç(Çѱ¹°úÇбâ¼ú¿ø)

±³À°½Ã°£ 04¿ù 20ÀÏ 300B 13:30~13:50 Generative AI in Medicine ±èÇʼö(³×À̹öŬ¶ó¿ìµå)

±³À°½Ã°£ 04¿ù 20ÀÏ 300B 13:50~14:10 Can ChatGPT Replace Cardiologists? ±èÁÖÇö(°í·ÁÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 300B 14:10~14:30 Legal Issues Presented by Generative AI ÀÌ»ó¿±(°í·Á´ëÇб³)

Åä·Ð 04¿ù 20ÀÏ 300B 14:30~14:40 Discussion ()

ÈÞ½Ä 04¿ù 20ÀÏ 14:40~14:50 Break ()

±³À°½Ã°£ 04¿ù 20ÀÏ 300B 14:50~15:10 ½ÉÀåÀçÈ°, °ú°Å, ÇöÀç¿Í ´çÀ§¼º ¼ºÁöµ¿(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 300B 15:10~15:30 ³ªÀÇ ½ÉÀåÀçÈ° ´ä»ç±â °ø¹Î±Ô(¼øõÇâÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 300B 15:30~15:50 ³ªÀÇ ½ÉÀåÀçÈ° È°µ¿±â ±è°æÈñ(ÀÎõ¼¼Á¾º´¿ø)

±³À°½Ã°£ 04¿ù 20ÀÏ 300B 15:50~16:10 ½ÉÀåÀçÈ°ÀÇ ¹Ì·¡¿¡ ´ëºñÇÑ ³ªÀÇ Áغñ±â ÀÌÂùÁÖ(¿¬¼¼ÀÇ´ë)

Åä·Ð 04¿ù 20ÀÏ 300B 16:10~16:20 Discussion ()

±³À°½Ã°£ 04¿ù 20ÀÏ 300C 09:00~09:20 Vascular Calcification in Patients with Chronic Kidney Disease: Understanding Pathophysiology °í°­Áö(°í·ÁÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 300C 09:20~09:40 Calcium Supplements: Good for the Bone, Bad for the Vessel? ÀÌÀ¯ºó(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 300C 09:40~10:00 Clinical Implications of Valvular Calcification ±è¼Ò¸®(°í·ÁÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 300C 10:00~10:20 Assessment and Management in Asymptomatic Coronary Calcification ÃÖ±âÈ«(¼º±Õ°üÀÇ´ë)

Åä·Ð 04¿ù 20ÀÏ 300C 10:20~10:30 Discussion ()

ÈÞ½Ä 04¿ù 20ÀÏ 10:30~10:40 Break ()

±³À°½Ã°£ 04¿ù 20ÀÏ 300C 10:40~11:00 Atrial fibrillation progression and burden: concept and clinical implication ¾çÇʼº(Â÷ÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 300C 11:00~11:20 Mitral regurgitation and tricuspid regurgitation in atrial fibrillation: an update Â÷¸íÁø(¿ï»êÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 300C 11:20~11:40 Optimal management of atrial high rate episodes: anticoagulation and antiarrhythmic drugs ±Ç¼øÀÏ(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 300C 11:40~12:00 SGLT2 inhibitors and atrial fibrillation: current evidences and future perspectives ¾ÈÁøÈñ(ºÎ»êÀÇ´ë)

Åä·Ð 04¿ù 20ÀÏ 300C 12:00~12:10 Discussion ()

ÈÞ½Ä 04¿ù 20ÀÏ 12:10~12:15 Break ()

±³À°½Ã°£ 04¿ù 20ÀÏ 300C 12:15~12:35 State-of-the-art: Optimal Management of Stroke Prevention in Elderly Patient with AF ½ÉÀç¹Î(°í·ÁÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 300C 12:35~12:55 Real-world Effectiveness and Safety of Sevikar HCT in Korean Patients with Hypertension and High-risk Factors ¿ÀÀç¿ø(¿¬¼¼ÀÇ´ë)

ÈÞ½Ä 04¿ù 20ÀÏ 12:55~13:10 Break ()

±³À°½Ã°£ 04¿ù 20ÀÏ 300C 13:10~13:30 Ablation for Inappropriate Sinus Tachycardia; When, How? ÀÌ»óÈñ(Æ÷Ç×¼¼¸í±âµ¶º´¿ø)

±³À°½Ã°£ 04¿ù 20ÀÏ 300C 13:30~13:50 Cardioneuroablation for Treatment of Bradycardia and Neurally Mediated Syncope ±èÈ­Áß(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 300C 13:50~14:10 Orthostatic Intolerance: Concept and Treatment ±è¼öÇö(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ 300C 14:10~14:30 Baroreflex Activation Therapy: Current Status ÃÖÁøÈñ(ºÎ»êÀÇ´ë)

Åä·Ð 04¿ù 20ÀÏ 300C 14:30~14:40 Discussion ()

ÈÞ½Ä 04¿ù 20ÀÏ 14:40~14:50 Break ()

±³À°½Ã°£ 04¿ù 20ÀÏ 300C 14:50~15:10 New insight on fascicular VT Chun Hwang(Prior Revere Health, USA)

±³À°½Ã°£ 04¿ù 20ÀÏ 300C 15:10~15:30 How to map and ablate VT in heart failure Eun-Sun Jin(/Kyunghee Univ., Korea)

±³À°½Ã°£ 04¿ù 20ÀÏ 300C 15:30~15:50 Update on VT in adult congenital heart disease Jae-Sun Uhm(Yonsei Univ., Korea)

±³À°½Ã°£ 04¿ù 20ÀÏ 300C 15:50~16:10 New insight on imaging for VT ablation Masateru Takigawa(Tokyo Medical & Dental Univ, Japan)

Åä·Ð 04¿ù 20ÀÏ 300C 16:10~16:20 Discussion ()

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2024 Ãá°è½ÉÇ÷°üÅëÇÕÇмú´ëȸ(2ÀÏÂ÷) : 2024-04-20""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2024³â ´ëÇÑÇǺΰúÀÇ»çȸ ´ë°æÁöºÎ ±³À°½ÉÆ÷Áö¾ö : 2024-04-20
´ÙÀ½±Û 2024 Çѱ¹³ë³â¿Ü°ú¿¬±¸È¸ Ãá°è½ÉÆ÷Áö¾ö : 2024-04-20
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20613 ´ë±¸ ´ëÇѽºÆ÷Ã÷ÀÇÇÐȸ Sports Medicine Symposium 2024 in Daegu : 2024-06-23 0 0 2024-04-29
20612 ¼­¿ï 2024³â ´ëÇÑ°ñ´ë»çÇÐȸ Á¦12Â÷ Clinical Densitometry Course : 2024-06-23 0 1 2024-04-29
20611 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 1Â÷(2ÀÏÂ÷) : 2024-06-22 0 0 2024-04-29
20610 ¼­¿ï ¼­¿ï¾Æ»êº´¿ø (¿Â¶óÀÎ) 6¿ù 21ÀÏ ±Ý¿äÁý´ãȸ(ÀÌ°ü ÁúȯÀÇ Áø´Ü°ú Ä¡·á) : 2024-06-21 0 1 2024-04-29
20609 °æ±â ¾È»ê ¹× ½ÃÈ­Áö¿ª À̺ñÀÎÈÄ°ú Àǻ縦 À§ÇÑ Áý´ãȸ(¾È¸é¸¶ºñ) : 2024-06-21 0 0 2024-04-29
20608 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 1Â÷(1ÀÏÂ÷) : 2024-06-21 0 1 2024-04-29
20607 ¼­¿ï 2024 ´ëÇÑȯ°æõ½ÄÆóÁúȯÇÐȸ Ãá°èÇмú´ëȸ : 2024-06-21 0 0 2024-04-29
20606 ¼­¿ï (¿Â¶óÀÎ)À̺ñÀÎÈÄ°ú Áö¿ªÀÇ»çÁý´ãȸ-¿Ü·¡¿¡¼­ °£´ÜÇÏ°Ô ÇÒ ¼ö ÀÖ´Â À½¼ºÄ¡·á : 2024-06-20 0 2 2024-04-29
20605 ´ë±¸ ´ëÇÑ»êºÎÀΰúÇÐȸ ´ë±¸Áöȸ ¿¬¼ö°­Á : 2024-06-20 0 1 2024-04-29
20604 °­¿ø Á¦171ȸ ÇѸ²´ëÇб³Ãáõ¼º½Éº´¿ø ¼ÒÈ­±â ¿¬¼ö±³À° : 2024-06-19 0 0 2024-04-29
20603 °æ±â Á¦16ȸ ±¹¸³¾Ï¼¾ÅÍ ±¹Á¦½ÉÆ÷Áö¾ö : 2024-06-19 0 2 2024-04-29
20602 ¼­¿ï ´ëÇѽÅÀåÇÐȸ APCN & KSN 2024 4ÀÏÂ÷ : 2024-06-16 0 5 2024-04-29
20601 ¼­¿ï [¿Â¶óÀÎ] Áø´Ü¿ë ¹æ»ç¼± ¾ÈÀü°ü¸®Ã¥ÀÓÀÚ ¼±ÀÓ±³À° : 2024-06-16 0 1 2024-04-29
20600 ¼­¿ï 2024 Á¦ 2ȸ ¿¬¼¼´ëÇб³ ¼öºÎ ¹× »óÁö ½ÉÆ÷Áö¾ö : 2024-06-16 0 0 2024-04-29
20599 ¼­¿ï ´ëÇÑ»êºÎÀΰú³»ºÐºñÇÐȸ ¿¬¼ö°­Á : 2024 »êºÎÀΰú¹Ì¼º³â¿¬¼ö°­Á : 2024-06-16 0 0 2024-04-29
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷